Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy

Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Buy rating and a price target of $56.00.

The analyst comments "We initiate coverage with a BUY rating and a $56 PT. Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade (C1s inhibition), may offer similar efficacy as available complement (C5) inhibitors, but with a cleaner safety profile. The recent Ph 2 proof-of-concept (PoC) results with claseprubart in generalized myasthenia gravis (gMG) were overall supportive of this thesis. In our view, gMG data are also relatively de-risking for the ongoing Ph 3 chronic inflammatory demyelinating polyneuropathy (CIDP) trial, for which we see significant upside potential upon positive data in 2H26."

For an analyst ratings summary and ratings history on Dianthus Therapeutics click here. For more ratings news on Dianthus Therapeutics click here.

Shares of Dianthus Therapeutics closed at $34.42 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Bitwise partners with Superstate to explore tokenized ETF shares